Cargando…
Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells
Myeloablative therapy with highdoses of the cytostatic drug melphalan (MEL) in preparation for hematopoietic cell transplantation is the standard of care for multiple myeloma (MM) patients. Melphalan is a bifunctional alkylating agent that covalently binds to nucleophilic sites in the DNA and effect...
Autores principales: | Poczta, Anastazja, Krzeczyński, Piotr, Ionov, Maksim, Rogalska, Aneta, Gaipl, Udo S., Marczak, Agnieszka, Lubgan, Dorota |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693175/ https://www.ncbi.nlm.nih.gov/pubmed/36430734 http://dx.doi.org/10.3390/ijms232214258 |
Ejemplares similares
-
Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells
por: Poczta, Anastazja, et al.
Publicado: (2022) -
Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches
por: Poczta, Anastazja, et al.
Publicado: (2021) -
Antileukemic activity of novel adenosine derivatives
por: Poczta, Anastazja, et al.
Publicado: (2019) -
Chemical modification of melphalan as a key to improving treatment of haematological malignancies
por: Gajek, Arkadiusz, et al.
Publicado: (2020) -
The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)